Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00078910 · ClinicalTrials.gov registry record · Phase 2

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
130
Enrollment target

NCT00078910: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT00078910 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 130 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00078910, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
130 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy, such as exisulind, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant exisulind works in treating patients who are undergoing radical prostatectomy for stage II or stage III prostate cancer.

Interventions

  • PROCEDURE conventional surgery
  • DRUG exisulind
  • PROCEDURE neoadjuvant therapy

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2003-08
Est. Completion 2006-09
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00078910 record still lists

NCT00078910 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 3 interventions - of which conventional surgery is the first listed.

NCT00078910 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00078910 about?

NCT00078910 is a clinical study titled "Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer". RATIONALE: Drugs used in chemotherapy, such as exisulind, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant exi...

What is the current status of trial NCT00078910?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2003-08. Estimated completion is 2006-09.

What interventions are being tested in trial NCT00078910?

The interventions under investigation include: conventional surgery (PROCEDURE), exisulind (DRUG), neoadjuvant therapy (PROCEDURE).

Who is sponsoring clinical trial NCT00078910?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00078910's enrollment target sits among peer trials

130 543rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00078910, the US trial registry maintained by the National Library of Medicine. NCT00078910 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.